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INTRODUCTION
Snake-bite is an important and serious emergency medical problem in many parts 
of the world, especially in South Asian countries. There are more than 3500 species of 
snakes worldwide of which only 300 are poisonous.  There are about 330 species of 
snakes found in India of which 70 are poisonous. It has been estimated that annually 
India records about 10000-15000 deaths due to snake bite. Case fatality rate is 2-10%. 
The most  common Indian venomous snakes referred to as  “Big Four” are  the krait, 
common cobra, saw-scaled viper & russell’s viper.
Most  snake  bites  are  accidental  and  inflicted  on  lower  limbs  of  high  risk 
population  such  as  children  while  playing  or  working  in  field.  Seasonal  peaks  in 
incidence are associated with onset of rainy season, flooding & rice harvesting season 
and occasionally during construction of new building.
CLASSIFICATION
There are two important groups of venomous snakes in South East Asia
Elapidae – cobra, mamba, krait, coral snakes, garter snakes, sea snakes.
Viperidae – saw scaled viper, russell’s viper, rattle snakes.
IDENTIFICATION OF SNAKES
There  is  no  simple  rule  for  identifying  a  dangerous  venomous  snake.  Some 
harmless snakes have evolved to look almost  identical to venomous ones.  However, 
some of the most notorious venomous snakes can be recognized by their size, shape, 
colour, pattern of markings, their behaviour and the sound they make when they feel 
threatened. For example, the defensive behaviour of the cobras is well known, they rear 
up, spread a hood, hiss and make repeated strikes towards the aggressor. Colouring can 
vary  a  lot.  However,  some patterns,  like  the  large white,  dark rimmed spots  of  the 
Russell’s  viper,  or  the  alternating  black  and  yellow  bands  of  the  banded  krait  are 
distinctive.  The blowing hiss of the Russell’s viper and the grating rasp of the saw-
scaled viper are warning and identifying sounds. 
 SNAKE 
Flat, compressed tail 
(Sea snake: venomous) 
Cylindrical tapering tail 
(Land snake) 
Small belly scales 
(Non venomous) 
Broad belly scales not extending 
across the entire width (Non 
venomous) 
Broad belly scales extending across 
the entire width 
Large scales on head 
(Viper: Venomous) 
Small scales on head with pit 
between nose and eye 
(Pit viper: Venomous) 
Large shield on head 
3rd upper lip shield touches the eye 
and nose shield 
Central row of scales on back 
enlarged and hexagonal, bands 
or half-rings on back, subcaudals 
undivided 
(Krait: Venomous) 
None of these characteristics 
(Non venomous 
Neck with hood and markings 
(Cobra: Venomous) 
Coral spots on belly 
(Coral snakes: Venomous) 
FANG MARKS
As previously believed, bite marks are not useful indicators of poisoning. This is 
because many venomous species possess more than one set of fangs and non venomous 
species can leave two puncture marks from enlarged teeth, which can appear to be fang 
like.
PATHOPHYSIOLOGY
Snake venom has 20 or more components of which more than 90 percent of dry 
weight is protein. It is in the form of enzymes, non-enzymatic polypeptide toxins and 
non  toxic  proteins.  The  remaining  10  percent  are  non  protein  ingredients  such  as 
carbohydrates and metals often in the form of glycoproteins.
Enzymes:
Venom procoagulants
RVV-x, a glycoprotein produced by russell’s viper activates factor X by calcium 
dependent mechanism and also acts on factor IX and protein C. 
arginine ester hydrolase activates factor V.
Eccarin activates prothrombin. 
Serine proteases cleaves fibrinopeptide-A from fibrinogen molecules.
Phospholipases-A2 –  It  is  the  most  widespread  of  the  venomous  enzymes.  It 
damages mitochondria, red blood cells, leucocytes, platelets, skeletal muscles, vascular 
endothelium and other membranes leading to myotoxicity, neurotoxicity, cardiotoxicity, 
hemolysis and increased vascular permeability.
Hyaluronidase – It promotes the spread of venom through tissues.
Hydrolases – It is responsible for the local changes in vascular permeability leading to 
edema, blistering, bruising and necrosis.
Nonenzymatic polypeptide toxins:
These are found in elapid venoms (cobra, krait). It consists of postsynaptic and 
presynaptic  toxins.  The  postsynaptic  neurotoxins  are  α bungarotoxin and cobrotoxin 
which  binds  to  the  acetycholine  receptors  at  the  motor  end  plate.  The  presynaptic 
neurotoxins are ß bungarotoxin, crotoxin, etc which block the release of acetylcholine at 
neuromuscular junctions.
Average yield per bite in terms of dry weight of lyophilized venom is 60 mg for 
cobra,  63  mg  for  russell’s  viper,  20  mg for  krait  and  13  mg  for  saw scaled  viper. 
Respective fatal doses are 12, 15, 6&8 mg.
PATHOLOGICAL PROCESS EFFECT
Direct cytolytic action Local necrosis and secondary 
infection
Procoagulants leading to 
intravascular coagulation & DIC
Bleeding
Platelet function defects Bleeding
Postsynaptic and presynaptic 
blockade
Neurotoxicity
RBC membrane destruction Intravascular hemolysis
Direct damage to tubules of 
kidney, renal ischaemia & 
hemolysis
Acute renal failure
Increased capillary permeability Edema, pulmonary edema, serous 
effusions
Decreased intravascular volume Shock
Cardiotoxicity Hypertension. ECH changes, acute 
myocardial infarction
FACTORS DETERMINING THE SEVERITY
1. AGE – younger the age more severe the manifestations.
2. LOCATION – bites over face, neck, trunk and superficial vessels are fatal.
3. POST SNAKE BITE ACTIVITY – exertion or running after the bite increases the 
venom absorption.
CLINICAL FEATURES
NON SPECIFIC MANIFESTATIONS
The non specific symptoms that are due to snake bite are vomiting, headache, 
myalgia,  vertigo,  tingling  and  numbness  over  tongue,  mouth  &  scalp  and 
hypersalivation. These symptoms are not related to the venom per se. They are often due 
to fear and anxiety. The duration from time of bite to time of onset of poisoning may be 
as early as 5 minutes in cobra or as late as 10 hours in krait bites. In viper the mean 
duration of poisoning is 20 minutes and for seasnakes it is usually within 2 hours.
SPECIFIC MANIFESTATIONS
ELAPIDAE (COBRAS, KRAIT)
The  local  effects  due  to  envenomation  by  elapids  are  tender  swelling  with 
regional  lymphadenopathy  and  blistering  within  24  hrs.  There  may  be  superficial 
necrosis  which  may  be  extensive.  If  there  is  secondary  infection  it  may  lead  on to 
gangrene and the patients may loose their digits, which causes increased morbidity. The 
local effects are minimal in krait.
The  venoms  of  the  elapids  are  best  known  for  their  neurotoxic  effects.  The 
paralysis is usually first detected as ptosis followed by external ophthalmoplegia. Other 
muscles  involved  later  are  face,  palate,  jaw,  tongue,  vocal  cord,  neck  muscles  and 
muscles of deglutition. Respiratory failure in early stages may be due to obstruction of 
airway  by  paralyzed  tongue  or  vomiting.  In  later  stages  it  is  due  to  paralysis  of 
intercostals muscle  or  diaphragm. Loss of consciousness and convulsions are  due to 
hypoxemia  secondary  to  respiratory  paralysis.  Neurotoxic  effects  are  completely 
reversible either acutely in response to antivenom or anticholinesterase effect or may 
wean of spontaneously in 1 to 7 days.
VIPERIDAE (RUSSELL’S VIPER, SAW SCALED VIPER)
The local reactions are severe in viper bites. The swelling due to envenomation 
spreads  very  rapidly.  There  is  usually  associated  pain,  tenderness  and  lymph  node 
enlargement. Bruising may be seen especially along the path of the lymphatics. Blisters 
may be seen which are filled with clear or blood stained fluid. There may be necrosis of 
the skin, subcutaneous tissue and muscle which may lead to compartment syndrome. 
Absence of pulse, sudden severe pain and a demarcated cold limb suggests thrombosis 
of a major artery.
The hemostatic abnormalities that are characteristic of viper bites are persistent 
bleeding from fang puncture wounds, venepuncture or injection sites and these may be 
the  first  clinical  sign  of  bleeding  diathesis.  There  could  be  gingival  hemorrhages, 
epistaxis,  hematemesis,  ecchymosis,  hemoptysis,  hematuria,  subconjunctival  and 
intracranial hemorrhages. Hypotension and shock are common due to the extravasation 
of  fluid  into  the  swollen  limb.  Hemoglobinuria  may  be  present,  suggestive  of 
intravascular hemolysis. Activation of coagulation cascade may lead on to disseminated 
intravascular coagulation which may further exacerbate the bleeding. Due to increased 
vascular permeability there may be serous effusions and pulmonary edema. Renal failure 
is the major cause of death in viper bites. It may be due to the direct toxic effect of the 
toxin or due to renal ischaemia and intravascular hemolysis.
INVESTIGATIONS
Investigations  are  used  for  monitoring  the  patient  and  determining  the  type  of 
envenomation.
• Complete blood count – anemia, thrombocytopenia
• Peripheral smear – evidence of hemolysis and DIC
• Coagulation profile – increased bleeding time, clotting time and prothrombin time
o 20 minutes whole blood clotting time – It was adopted as the standard test for 
coagulopathy. It is simple to carry out but crucially requires a clean, new and 
dry  test  tube.  A few mL of  fresh  venous  blood is  left  undisturbed for  20 
minutes, and then gently tilted. If the blood is still liquid this is evidence of 
coagulopathy and confirms that the bite is by Viper species. Cobras or Kraits 
do not cause anti-haemostatic symptoms.
• Renal function tests
• Serum Electrolytes – hyperkalemia may be present
• Urinalysis – RBC’s, RBC cast or hemoglobin may be seen
• ECG – changes are usually nonspecific and include bradycardia, AV block with 
ST segment elevation or depression and features suggestive of hyperkalemia.
TREATMENT
First aid
As 70 percent of all snakebites are from non venomous species and only 50% of 
bites  by  venomous  species  actually  envenomate  the  patient,  reassure  the  patient  to 
prevent exertion and anxiety. As movement increases the venom absorption immobilize 
the limbs in the same way as a fractured limb. Children can be carried. Use bandages or 
cloth to hold the splints, not to block the blood supply or apply pressure. Do not apply 
any compression in the form of tight ligatures. Tourniquets and pressure immobilization 
methods are not used in India. Incision, suction, electric shock, cryotherapy and washing 
are contraindicated.
Criteria for Antisnake venom administration
• Severe local symptoms – swelling rapidly crossing a joint or involving half of the 
bitten limb in the absence of tourniquet.
• Increased 20 minutes whole blood clotting time or spontaneous bleeding.
• Neurological impairment such as ptosis.
Dose of ASV
The initial  ASV dose is  a subject  of debate.  As russell’s  viper  on an average 
injects about 63 mg of venom in the first bite to both adults and children, logic is to 
administer ASV to neutralize this amount of venom. One vial of ASV neutralizes 6 mg 
of russell’s viper venom. So a total of 8-10 vials may be required for the initial dose3. 
The range of venom injected is 5 – 147 mg. so a maximum of 25 vials may be required. 
There is no evidence to suggest children should receive either more ASV because of 
body mass or less in order to avoid adverse reactions. The total dose of ASV is to be 
administered over 1 hour.
Adverse effects
Adverse  effects  to  antisnake  venom may  be  due  to  anaphylaxis  or  pyrogenic 
reactions. If handled early with the primary drug of choice, these reactions are easily 
surmountable. Early intervention against these kind of reactions has been shown to have 
more  positive  outcomes.  The  reactions  are  urticaria,  itching,  fever,  chills,  nausea, 
vomiting,  diarrhea,  abdominal  cramps,  tachycardia,  hypotension,  bronchospasm  and 
angioedema.  On  the  appearance  of  any  one  of  the  reactions  ASV  should  be 
discontinued. Adrenaline 0.01 mg/kg (1 in 1000 solution) is the drug of choice. It should 
be given intramuscularly as absorption is fast (usually within 8 minutes). Adrenaline can 
be  repeated  every  10  minutes  to  a  maximum of  three  doses.  For  longer  protection 
Hydrocortisone 2 mg/kg and antihistaminics (pheniramine maleate 0.2 mg/kg) should be 
administered. After the reactions have subsided ASV should be restarted slowly. ASV 
test dose is abandoned since they have no predictable value in anaphylactoid or late 
serum reactions and they also pre-sensitize the patient to proteins2, 3.
Repeat doses of ASV
If  the 20 minutes Whole Blood Clotting Time after  6 hrs  is  prolonged or  the 
cellulitis is increasing then ASV should be repeated. In case of neurotoxic bites once the 
initial  10  vials  and  neostigmine  0.05  mg/kg  has  been  given  monitor  the  patient.  If 
condition does not improve or it worsens within 1-2 hrs then a second and final dose 
should be given. If there is no improvement after second dose, the further ASV is of no 
use and the patient is managed with ventilator.
Supportive management
Fluid management and ionotropes
Avoid IM injections
Analgesics and sedatives
Broad spectrum antibiotics with anaerobic cover
Blood component transfusion
Local wound management
Dialysis if acute renal failure is present
Fasciotomy if compartment syndrome is present
REVIEW OF LITERATURE
1) Adhisivam et  al6 did  a  retrospective  study  in  the  Department  of  Pediatrics, 
Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), 
a tertiary care hospital at Pondicherry to study the clinical profile of snake bite 
envenomation. During the study period of 34 months (Nov 2002 to Aug 2005), 50 
children  (9  months  to  12  years  of  age)  were  admitted  for  snake  bite 
envenomation.  42  % of  the  bites  were  hemotoxic  and  8  % were  neurotoxic. 
Number  of  deaths  due  to  the  snake  bite  was  9  (18%)  and  all  were  due  to 
hemotoxic  bites.  Complications  like  Disseminated  intravascular  coagulation 
(10%) and acute renal failure (18%) were present. 4 of them required ventilator 
support (all were neurotoxic bites). Local cellulitis was present in 66 % of the 
patients. Average Antisnake venom required was 100 ml (10 vials). Anaphylaxis 
to Antisnake venom was seen in 12 % of cases. Average PICU stay was 2 days. 
There is an urgent need to educate the rural population about the hazards and 
proper first aid for snakebites. Ready availability and appropriate use of antisnake 
venom, close monitoring of patients, and timely institution of ventilatory support 
help  in  reducing  the  mortality.  Randomised  controlled  trials  are  needed  to 
investigate regarding rationale use of antivenom treatment.
2) Sharma N et  al7 did  a  study  on clinical  profile  of  snake  bite  in  postgraduate 
institute of medical science and research. It was a retrospective study of all snake 
bite cases admitted from January 1997 to December 2001. Of a total of 142 cases 
of snakebite there were 86 elapid bites presenting with neuroparalytic symptoms 
and 52 viper  bites  having haemostatic  abnormalities.  Urban to  rural  ratio  was 
1:4.7 and male to female ratio was 4.25:1. Median time to arrival at our hospital 
after the bite was nine hours and mean duration of hospital stay was eight days. 
Twenty seven cases had acute renal failure and 75% of all elapid bites required 
assisted ventilation. Seventeen of 119 patients who received antivenom had an 
adverse event. The average dose of antivenom was 51.2 vials for elapid bites and 
31 vials for viper bites. Overall mortality rate was 3.5%. Snakebites are common 
in the rural population of developing countries. There is a need to educate the 
public about the hazards of snakebite, early hospital referral, and treatment.
3) Suchithra  N et  al8 has  done  a  study  to  determine  the  clinical  characteristics, 
factors  involved  in  complications  and  the  outcome  in  relation  to  timing  of 
polyvalent  snake  antivenom  administration  in  patients  with  snakebite 
envenomation. It was a retrospective study and all snake bite cases admitted to the 
emergency  care  unit  of  Kottayam  Medical  College  between  May  2005  and 
December  2006  were  taken.  200  (34%)  of  586  cases  with  snakebites  had 
envenomation.  The species of snake was identified in 34.5% of the venomous 
bites. 93.5% had signs of local envenoming. Regional lymphadenitis occurred in 
61%. The mortality rate was 3%. Capillary leak syndrome, respiratory paralysis 
and intracerebral bleeding were the risk factors for mortality. Those who received 
Snake  antivenom  early  (bite  to  needle  time  <6  h)  had  more  severe  local 
envenomation than those who received Snake antivenom late (bite to needle time 
>or =6 h), but the latter group were more likely to suffer complications. 39.5% 
had  complications,  with  acute  renal  failure  being  the  most  common  (25.5%). 
Those who received Snake antivenom late had a higher risk of developing acute 
renal  failure.  Higher  rates  of  complications  were  seen  in  those  with  severe 
coagulopathy, leucocytosis and those who received Snake antivenom late. Early 
administration  of  Snake  antivenom  reduces  the  risk  of  complications.  The 
presence of leucocytosis and severe coagulopathy can predict adverse outcomes.
4) Bawaskar  et  al9 did  a  retrospective  study  in  Bawaskar  Hospital  and Research 
Centre,  Mahad  Raigad,  Maharashtra  to  determine  the  profile  of  snakebite 
envenomation  in  Western  Maharashtra.  Ninety-one  cases  of  snakebite  were 
admitted  between  January  1998  and  January  2001  to  the  general  hospital  at 
Mahad. Forty-five (49.5%) patients had snakebite without envenomation. Twenty-
six (28.6%) patients were paralyzed. Twenty-nine (31.9%) patients brought the 
snakes responsible for the bites (20 kraits, 9 Echis carinatus). 27 patients had local 
fang marks without local and systemic manifestations. Ten (11.0%) patients died, 
3 on the way to hospital and 7 during treatment. Out of 7 cases transferred for 
tertiary care, 6 recovered and 1 died on the way to Mumbai. Early administration 
of anti-snake venom (ASV), endotracheal intubation and timely intervention with 
mechanical  ventilation and anticholinesterase treatment  for  Elapidae (krait  and 
cobra) envenomation are crucial for saving lives.
5) Punde  DP10 did  a  study  in  Punde  hospital  Mukhed,  Nanded,  Marathwada, 
Maharashtra to determine the pattern of snake-bites and their management in a 
rural area of India over a 10 year period. A total of 633 patients with snake-bite 
admitted to the Rural Community Centre and Punde Hospital between 1992 and 
2001  were  analysed  retrospectively.  The  local  and  systemic  manifestations  of 
snake-bite, response to antisnake venom, atropine and neostigmine, the treatment 
of  complications  and  the  outcome  were  analysed.  Of  the  633  patients,  427 
(67.5%)  had  been  bitten  by  poisonous  snakes.  The  majority  of  snake-bites 
(68.9%)  occurred  between  May  and  November.  Of  the  427  envenomed  by 
poisonous snakes, 274 (64.2%) were by Echis carinatus (saw-scaled viper),  71 
(16.6%)  by  cobra,  42  (9.8%)  by  krait  and  40  (9.4%)  by  Russell  viper.  The 
requirement of antisnake venom for treating neurotoxic envenomation was 40-320 
ml and for Echis carinatus and Russell viper bites it was 20-250 ml. The mortality 
rate was 4.7%. Ready availability and appropriate use of antisnake venom, close 
monitoring of patients,  institution of ventilatory support and early referral to a 
larger hospital when required help in reducing the mortality. Most patients with 
snake-bites can be successfully managed even in small rural hospitals with limited 
facilities.
6) Bhardwaj A et al11 did a study in Central Research Institute, Himachal Pradesh to 
determine the risk factors exposing the population to snake bite and the common 
types  of  snakes  causing  them.  It  was  a  retrospective  study.  They  studied  243 
patients of snake bite over a period of 24 months. Seasonal variation in snake bite 
was seen, with a peak in the months of August and September. No bites were 
recorded in December, January and February. Eighty-four per cent of the bites 
were on the hands and feet (up to the ankle). Snake bites while sleeping were at 
uncommon sites. Non-poisonous snakes were the most common (90.5%). Kraits 
caused 60% of bites with envenomation. Snake bites occur frequently in the hills 
of Himachal Pradesh. Although snake bites are a cause for concern, most of them 
are caused by non-poisonous snakes.
7) Ganneru Brunda et  al12 did a study  to find out  the  Epidemiological  profile of 
snake-bite  cases  from  Andhra  Pradesh  using  immunoanalytical  approach in 
Department of Biochemistry, University College of Science, Osmania University, 
Hyderabad.  They  reported  a  retrospective  epidemiological  data  of  snake-bite 
incidence  in  Andhra  Pradesh  and prospective  assessment  of  the  snake  venom 
antigens  in  forensic  specimens  collected  from  snake-bite  victims  through 
immunoanalytical approach. Data from 1379 snake-bite cases were collected from 
case reports for a 5 yr period (1999-2003) that included age and sex of the victim, 
district,  month  and  time  of  incident,  death  of  a  victim and the  time  point  of 
analysis. On the basis of the forensic data, specimens were collected from forensic 
medicine department and were analysed for the venom antigens (cobra and krait) 
by ELISA method. The peak number of snake-bite cases was seen during June-
September. Higher incidence of snake-bite was recorded in males (76%). Of the 
22 cases analysed by ELISA, 6 was tested positive for  cobra venom, 8 cases 
tested positive for krait venom, the remaining specimens tested negative for both 
cobra  and  krait  venom.  The  conclusion  was  evaluation  of  forensic  specimens 
(autopsy and biopsy) of  human snakebite  victims based on specific  molecular 
epidemiological  tool  like  ELISA  gives  a  true  estimate  of  the  incidence 
supplementing clinical and circumstantial evidence.
8) Bawaskar  et al13 did a study in Bawaskar Hospital and Research Centre, Mahad 
Raigad,  Maharashtra  to  determine  the  envenomation  by  the  common  krait 
(Bungarus caeruleus) and Asian cobra (Naja naja), their clinical manifestations 
and management in a rural setting. They have collected 30 subjects of presumed 
snake envenoming (krait = 23 cases, cobra = 7 cases). Details of the bite site, the 
subject's  activities  at  the  time  of  the  bite,  local  manifestations,  systemic 
involvement, progress of venom poisoning, and subsequent response to treatment 
were collected on a standard data form. The type of snake was confirmed either 
by  analysing  the  killed  specimen  or  by  combining  clinical  findings  and 
identification by the subject or bystanders. Of 23 subjects bitten by kraits, 2 were 
deceased  upon  arrival,  7  died  in  the  hospital,  and  14  recovered.  Of  the  14 
survivors,  4 required artificial respirations with a resuscitation bag, antivenom, 
and  anticholinesterase  drugs.  The  remaining  9  recovered  with  supportive 
treatment only. Of 7 subjects encountering cobras, 2 who had been bitten were 
deceased upon arrival at the hospital, and 1 died suddenly of an apparent cardiac 
arrest  after  seeing  a  hooded  cobra  on  a  road.  Four  subjects  recovered  with 
antivenon,  anticholinesterase  drugs,  and/or  artificial  respiration.  Early 
administration of antivenom prevents respiratory paralysis after elapid snake bite. 
Patients  with  evidence  of  respiratory  insufficiency  after  neurotoxic  venom 
poisoning require rapid intubation and artificial ventilation.
9) Lal P et al14 did a retrospective study to find out the socio-demographic profile of 
snakebite cases admitted in JIPMER Hospital from 1990-1996. 865 cases were 
admitted during the period. Proportional case rate of snakebite cases increased 
from 2.9/1000 admissions  in  1990 to  5.2/1000 admissions  in  1996.  About  68 
percent of the cases were males. About 40 percent of cases were observed from 
the period of September to November which coincided with maximum rainfall. 
About  85  percent  of  cases  either  got  relieved  or  cured  and  13.5  percent 
experienced mortality.
K Narvencar15 did a study in Department of Medicine, Goa Medical College, Bambolim, 
Goa  to  find  out  the  relationship  between  the  time  of  anti-snake  venom  (ASV) 
administration due to late arrival of patient at hospital and subsequent development of 
complications. All patients of snake bite that presented to the institution over a period of 
1½ years  were included in the present  study.   The patients  were administered ASV 
within 10 minutes of presentation. The bite to needle time (time between the bite and 
start of ASV) was noted. The patients were then followed up to note any subsequent 
development  of  complications.  The  end-point  of  the  study  was  normalization  of 
haematological and neurological parameters. Fifty patients became eligible for the study. 
Twenty  patients  (40%)  had  complications  while  remaining  30  patients  (60%)  were 
uncomplicated. An attempt was made to study relationship between bite to needle time 
and subsequent development of complications. It was found to be significant at 5% level 
of significance. Incidence of complications was directly proportional to the duration of 
venom in the blood prior  to  neutralization by  ASV due to  late  arrival  of  patient  at 
hospital. The early institution of ASV is beneficial in preventing complications however 
severe is the systemic envenomation.
AIM OF THE STUDY
 To study the clinical profile and outcome of snake envenomation in children upto 
12 yrs of age in Government Rajaji Hospital, Madurai.
MATERIALS AND METHODS
Study centre:
The study was conducted in the Institute of Child Health and Research Centre, 
Government Rajaji Hospital, Madurai.
Study period:
The study period is from November 2006 to June 2008.
Study design:
Prospective study.
Inclusion criteria:
 All children <12 yrs with history of snake bite 
 Any child <12 yrs with history of unknown bite with any one of the following 
were taken into the study 
• Cellulitis involving more than 1/3rd of limb or crossing a joint
•  Prolonged whole blood clotting time of more than 20 minutes 
• Neurological signs of envenomation such as ptosis, external 
ophthalmoplegia, etc
Methodology:
After  obtaining  approval  by  the  ethical  committee  and  informed  consent,  all 
children <12 yrs who were admitted with snake bite were enrolled in the study. A total 
of 145 cases who met the above criteria were enrolled in the study. The patient’s age, 
sex,  site  of  bite,  duration  of  arrival  to  the  hospital  were  noted  down.  The  clinical 
manifestations of the patients were noted down and a detailed clinical examination was 
done. The investigations relevant were noted down. The number of vials of Antisnake 
venom given, their complications and their management were taken into account. The 
complications that occurred due to snake bite were noted down. All the children were 
followed till discharge or death. The outcome was recorded as alive or dead.
Statistical Tools
The  information  collected  regarding all  the  selected  cases  were  recorded in  a 
Master Chart. Data analysis was done with the help of computer using Epidemiological 
Information  Package  (EPI  2002)  developed  by  Center  for  Disease  Control  and 
Prevention (CDC), Atlanta for W.H.O.
Using  this  software,  frequencies,  percentages,  means,  standard  deviations,  chi 
square and ‘p’ values were calculated. Kruskul Wallis chi-square test was used to test 
the  significance  of  difference  between  quantitative  variables  and  Yate’s  test  for 
qualitative  variables.  A  'p'  value  of  less  than  0.05  is  taken  to  denote  significant 
relationship.
RESULTS
A: Characteristics of cases studies
Table 1: Age
Age in years
Cases
No %
Up to 4 years 17 11.7
5 – 8 years 49 33.8
9 – 12 years 79 54.5
Total 145 100
The number of cases seen is 17(11.7%) upto the age of 4 yrs, 49(33.8%) from 4-8 yrs 
and 79(54.4%) from 9-12 yrs. Most of the cases are between the age group of 9-12 yrs.
Table 2: Sex
99(68.3%) cases were males and 46(31.7%) cases were females with males being more 
common.
Sex
Cases
No %
Male 99 68.3
Female 46 31.7
Table 3: Months
Most of the bites have occurred between July and September with a total of 60(41.4%) 
cases.
Seasons
Jan - Mar 29 20
Apr - Jun 26 17.9
Jul - Sep 60 41.4
Oct - Dec 30 20.7
Table 4: Duration between time of snake bite and arrival at 
Hospital
Time interval in 
hours
Cases
No %
Less than 4 hours 89 61.4
4 – 8 hours 24 16.6
8 – 12 hours 9 6.2
More than 12 
hours
23 15.9
Total 145 100
89(61.4%) cases arrived within 4 hrs of bite, 24(16.6%) between 4-8 hrs, 9(6.2%) cases 
between 8-12 hrs and 23(15.9%) cases arrived after 12 hrs since bite.
Table 5: Site of bite
33(22.8%) cases had bite in upper limbs, 110(75.8%) cases had bite in lower limbs and 
2(1.4%) had bite in other areas.
Site of bite
Cases
No %
Upper limb 33 22.8
Lower limb 110 75.8
Others 2 1.4
Table 6: Treatment given outside
Treatment
Cases
No %
Injection (TT, etc) 24 16.6
I & D 4 2.8
ASV 26 18.1
I & D + ASV 1 0.7
Injections  were  given  24(16.6%)  cases,  Incision  and  Drainage  was  done  for 
4(2.8%) cases, Antisnake venom was given for 26(18.1%) cases and both Incision and 
Drainage and Antisnake venom was given for 1(0.7%) case.
Table 7: Cellulitis
Cellulitis
Cases
No %
Yes 89 61.4
No 56 38.6
Cellulitis was present in 89(61.4%) cases and absent in 56(38.6%) cases.
Table 8: Type of toxicity
Out  of  the  103  poisonous  bites  hemotoxicity  was  seen  in  77(53.1%)  cases, 
neurotoxicity in 8(5.5%) cases and in 18(12.4%) cases only cellulitis was seen.
Table 9: No of vials of ASV given initially
Type of toxicity
Cases
No %
Hemotoxic 77 53.1
Neurotoxic
8 5.5
Only cellulitis
18 12.4
No signs of 
envenomation
42 29
Out of all the poisonous bites 64(44.14%) cases received Antisnake venom upto 
10 vials and 33(22.8%) cases received more than 10 vials initially.
Table 10: Number of vials of ASV given initially and requirement of further ASV
Number of ASV 
Requirement of further ASV
Required (25) Not required  (72)
No % No %
Upto 10 vials (64) 18 28.1 46 71.9
More than 10 vials 
(33)
7 21.2 26 78.8
‘p’ value 0.4068
Not significant
No of vials of ASV
Cases
No %
Up to 10 Vials 64 44.14
More than 10 Vials 33 22.8
Not given 42 29
Table 11: Anaphylaxis to Antisnake venom
Anaphylaxis to ASV Cases
No %
Milder reactions (rash, itching, nausea, vomiting, 
etc)
23 22.3
Severe reactions (shock, bronchospasm, 
bradycardia, etc)
7 6.8
No reactions 67 70.9
Anaphylaxis in the form of milder reactions were seen in 23(22.3%) cases and 
severe reactions were seen in 7(6.8%) cases. 7(70.9%) cases had no reactions.
Table 12: Fang marks
Fang marks Poisonous
+ - Total
+ 63 31 94
- 40 11 51
Total 103 42 145
Out of the 103 poisonous bites 63 had fang marks and 40 did not have fang marks. 
Out of the 42 non poisonous bites 31 had fang marks and 11 did not have fang marks.
Table 13: Lymphadenopathy
Lymphadenopathy Poisonous Total
+ -
+ 58 - 58
- 45 42 87
Total 103 42 145
Out of the 103 poisonous bites 58 had tender lymphadenopathy and no case of 
non poisonous bite had lymphadenopathy.
Table 14: Complications
Complications
Poisonous bites (103)
No %
Renal failure
8 7.8
Encelphalopathy 1 0.98
Osteomyelitis 1 0.98
Gangrene 1 0.98
DIC 2 1.9
Total 
Complications
13 12.6
Table 15: Management of complications
Management of complications cases
No %
Blood component transfusion 11 7.6
Fasciotomy 6 4.1
Dialysis 3 2.1
Ventilator support 7 4.8
Table 16: Duration of Hospital stay
Duration Cases
No %
Up to 5 days 109 75.2
More than 5 days 36 24.8
The duration of hospital stay was less than 5 days for 109(75.2%) cases and more 
than 5 days for 36(24.8%) cases.
Table 17: Outcome
Outcome
Cases
No %
Alive 139 95.9
Death 6 4.1
Out of the 145 cases 139(95.9%) were alive and 6(4.1%) cases died.
Association between various parameters & outcome
Table   18: Age and outcome
Age group
Outcome
Alive Dead
No % No %
Up to 4 years 16 11.5 1 16.7
5 – 8 yrs 49 35.3 - -
9 – 12 yrs 74 53.2 5 83.3
Mean 8.19 yrs 9.0 yrs
S.D. 2.93 yrs 2.68 yrs
'p' 0.5290
Not significant
Table 19: Sex and Outcome
Sex
Outcome
Alive Dead
No % No %
Males (99) 94 94.9 5 5.1
Females (46) 45 97.8 1 2.2
'p' 0.3794
Not significant
Table 20: Duration between bite and arrival and outcome
Duration between bite and 
arrival
Outcome
Alive Dead
No % No %
Less than 4 hours (89) 85 95.5 4 4.5
4 – 8 hrs (24) 24 100 - -
8 – 12 hrs (9) 9 100 - -
More than 12 hours (23) 21 91.3 2 8.7
Mean 5.63 hours 7.33 hrs
S.D 5.72 hours 8.26 hrs
P 0.9093
Not significant
Table 21: Site of Bite & Outcome
Site of Bite
Outcome
Alive Dead
No % No %
Upper Limb (33) 32 97 1 3
Lower Limb 
(110)
105 95.5 5 4.5
Others (2) 2 100 - -
P 0.5788 
Not significant
Table 22: Type of Bite & Outcome
Type of Bite
Outcome
Alive Dead
No % No %
Hemotoxic (77) 72 93.8 5 6.5
Neurotoxic (8) 7 87.5 1 12.5
Only cellulitis(18) 18 100 - -
P 0.4579 
Not significant
Table 23: Number of ASV given initially & Outcome
Number of ASV
Outcome
Alive Dead
No % No %
Upto 10 vials (64) 61 95.3 3 4.7
More than 10 vials (33) 30 90.9 3 9.1
p 0.33 
Not significant
Table 24: Complications & Outcome
Complications
Outcome
Alive Dead
No % No %
Renal failure (8) 5 62.5 3 37.5
Encephelopathy(1) - - 1 100
Osteomyelitis (1) 1 100 - -
Gangrene (1) 1 100 - -
DIC (2) 1 50 1 50
Total 
Complications (13)
8 61.5 5 38.5
No Complications 
(90)
90 100 - -
p 0.0001 
Significant
DISCUSSION
A total of 145 cases with snake envenomation were enrolled during the period. 
Out of the 145 cases 103 were due to poisonous bites and 42 were due to non poisonous 
bites. The most common type of toxicity is hemotoxic which accounts for 77(53.1%) 
cases of  the total  103 poisonous cases compared to neurotoxic  which accounted for 
8(5.5%) cases and 18 cases presented only with cellulitis. This in contrast to the studies 
conducted by Sharma et  al7 & Bharadwaj  et  al11 in North India in which they have 
reported higher number of elapid bites.
The  commonest  age  group  in  this  study  is  9-12  yrs  which  accounted  for 
79(54.5%) cases of the total 145 cases. 99(68.3%) cases were males and 46(31.7%) of 
them were  females.  The  bites  were  more  common in  the  rainy  season between the 
months of July and September. Punde et al10 showed 68.9% of bites between May and 
December in their study.
Most of the bites have occurred while the children were playing outside the house. 
The most common site of bite is in lower limbs which were seen in 110(75.8%) cases. 
The bites which occurred during the sleep were more commonly seen over face and 
upper limbs.
The mean duration between the bite and arrival to the hospital is less than 4 hrs in 
89(61.4%) cases, 4-8 hrs in 24(16.6%) cases, and 8-12 hrs in 9 (6.2%) cases and more 
than 12 hrs in 23 (15.9%) cases. The cases which arrived late are mostly referred from 
other peripheral centers where they have received treatment for a short while. 
Out of the referred cases 24(16.6%) of them were given only injections, Incision 
& drainage was done for 4(2.8%) cases and 26(18.1%) cases have received Antisnake 
venom. The Antisnake venom that was given in the peripheral centers was less than 10 
vials in the 20 cases.
Out of the 103 poisonous bites,  89(61.4%) of them had cellulitis.  Fang marks 
were present in 94(64.8%) cases. But the decision on envenomation depending upon the 
fang marks is not reliable, because fang marks may or may not be present in poisonous 
bites and non poisonous bites can also have fang marks. Tender lymphadenopathy was 
present in 58(40%) cases and is a good indicator of envenomation because all the cases 
which had tender lymphadenopathy had signs of envenomation.
Antisnake venom was given for 97 cases out of the 103 poisonous bites. 6 cases 
were  not  given  Antisnake  venom  because  they  had  already  received  10  vials  of 
Antisnake venom from the referring hospital and there were no signs of toxicity at the 
time of presentation to our hospital. Out of this the initial dose given was less than or 
equal to 10 vials in 64(44.1%) cases and more than 10 vials in 33(22.8%) cases. More 
Antisnake venom was required for 18(28.1%) cases which initially received less than or 
equal to 10 vial of ASV. All the neurotoxic bites were managed with Antisnake venom, 
injection Neostigmine & atropine and ventilator support was given for those developed 
respiratory failure.
Anaphylaxis to ASV was seen in 30 cases. Out of the 30, milder reactions like 
rash, nausea, vomiting, fever, chills and itching were seen in 23(22.3%) cases and severe 
reactions like shock, bronchospasm and bradycardia were seen in 7(6.8%) cases. No 
reactions were seen in 67(70.9%) cases. The reactions were managed effectively with 
intramuscular adrenaline followed by steroids and antihistaminics.
Complications were seen in 13(12.6%) cases out of the 103 poisonous cases. The 
most common complication in our study was renal failure which occurred in 8(7.8%) 
cases. This is similar to the study done by adhisivam et al6 in JIPMER and Suchitra et al 
in  Kottayam8 in  which  he  showed  that  18%  of  the  cases  had  acute  renal  failure. 
Disseminated intravascular coagulation was seen in 2 (1.9%) cases, encephalopathy in 
1(0.98%)  case,  osteomyelitis  in  1(0.98%)  case  and  gangrene  in  1(0.98%)  case. 
Complications were managed with blood component transfusion (11), fasciotomy (6), 
dialysis (3) and ventilator support (7). Out of the total 145 cases 6 cases died with a 
mortality rate of 4.1%. The most common cause of death is acute renal failure. The 
mean duration of hospital stay is less than 5 days in 109(75.2%) cases and more than 5 
days in 36(24.8%) cases.
Out of the 8 neurotoxic cases, 1(12.5%) case died and out of the 77 hemotoxic 
bites 5(6.5%) cases died with a total mortality rate of 4.1%. So we can see from the data 
that  neurotoxic bites  carry a high mortality compared to hemotoxic bites.  The cases 
which arrived late (>12 hrs) had a higher percentage of mortality. There were 4(4.5%) 
deaths in cases which arrived within 4 hrs and 2(8.7%) deaths in cases which arrived 
after 12 hrs of bite. There were 3 deaths each in the patients who received initially upto 
10 vials and more than 10 vials.
The outcome of  the cases mainly depends upon the complications.  There is  a 
statistical significance stating that increase in complications leads to increased mortality. 
The  mortality  was  high  in  cases  which  had  renal  failure,  encephalopathy  and 
disseminated intravascular coagulation.
CONCLUSION
Snake bites are still a common problem in the rural areas of the country. As we 
can see from the study, hemotoxic snakes are the most common cause of bites. Even 
though neurotoxic bites are less common, mortality is more in them. The complications 
and  mortality  is  high  in  cases  which  arrived  late.  So  early  referral  and  early 
administration of ASV is life saving. If complications develop adequate management 
with dialysis, fasciotomy and ventilator support reduces morbidity and mortality. In this 
study all  the  complications  of  Antisnake  venom were  managed with adrenaline  and 
supportive measures and there is no mortality due to anaphylactic reactions of ASV. So 
ASV can be safely administered in peripheral health centers and complications can be 
managed.  So  ready  availability  and  appropriate  use  of  antisnake  venom  helps  in 
reducing the mortality. Most of the cases of snake bite can be managed in small rural 
hospitals with limited facilities.
LIMITATION OF THE STUDY
 As the number of cases is low, statistical significance among various parameters 
could not be established.
RECOMMENDATIONS
 Educate the rural people regarding the hazards of the snake bite, first aid measures 
and early referral to hospital.
 Antisnake venom should be readily available in peripheral health centers in 
adequate amounts and most of the cases can be treated in peripheral centers 
successfully.
 If complications develop, early referral to tertiary hospital reduces the mortality.
SUMMARY
Objective: To study the clinical profile of snake bite in children. 
Methods: It  is  a  prospective  observational  study  conducted  in  Government  Rajaji 
Hospital,  Madurai.  Results: A  total  of  145  cases  were  studied  during  the  period. 
Hemotoxic snakes (77) accounted for the most number of bites. The cases which arrived 
late  after  the  bite  suffered  more  complications  and  mortality.  The  most  common 
complication in this study is acute renal failure. The mortality rate is 4.1%. The patients 
who had complications had a high mortality  rate.  So early  recognition,  treatment of 
envenomation and referral to higher center if complications develop helps in reducing 
the mortality.
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PROFORMA
CLINICAL  PROFILE  OF  SNAKE  BITE  IN  CHILDREN  IN  GOVT.  RAJAJI 
HOSPITAL
S.NO:
NAME: AGE: SEX:
ADDRESS: RURAL/URBAN
SYMPTOMS:
TIME OF BITE:
TIME OF ARRIVAL TO HOSPITAL:
SITE OF BITE:
LOCATION OF BITE:
TYPE OF SNAKE: TOLD/BROUGHT
PAIN:
SWELLING:
BLEEDING FROM LOCAL SITE:
BLEEDING FROM GUMS:
VOMITING:
HEADACHE:
INCREASED SALIVATION:
SWEATING:
PTOSIS:
OLIGURIA:
HEMATURIA:
RESPIRATORY DISTRESS:
H/O OF FIRST AID: TUNICAE/ I&D/ INJECTIONS
ON EXAMINATION:
     PR      RR      BP     CRT    TEMP
CONSCIOUS:
BLEEDING FROM GUMS:
PTOSIS:
RESPIRATORY DISTRESS:
LOCAL EXAMINATION:
FANG MARKS:
SWELLING:
TENDERNESS:
ECHYMOSIS:
BLEEDING:
NECROSIS:
LYMPHADENOPATHY:
CARDIOVASCULAR SYSTEM:
RESPIRATORY SYSTEM:
CENTRAL NERVOUS SYSTEM:
ABDOMEN EXAMINATION:
INVESTIGATIONS:
BLEEDING TIME: CLOTTING TIME:
COMPLETE BLOOD COUNT:
BLOOD UREA & CREATININE:
TREATMENT:
GRADING OF ENVENOMATION:
TIME OF START OF ANTIVENOM:
TIME OF COMPLETION OF ANTIVENOM:
NO OF VIALS OF ANTIVENOM USED:
COMPLICATIONS OF ANTIVENOM:
ANTIBIOTICS:
BLOOD TRANSFUSION:
COURSE IN HOSPITAL:
PROGRESSION OF CELLULITIS:
RENAL PARAMETERS:
ANY FURTHER ASV GIVEN:
DIALYSIS:
FASCIOTOMY:
RESPIRATORY SUPPORT:
DURATION OF HOSPITAL STAY:
OUTCOME
MASTER CHART
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13 9 yrs F a b - - - - + - - - - - - -
14
11 
yrs F a b - - - - - - - - - - - -
15
10 
yrs M b b - - - a + - - - - - - -
16
12 
yrs M a b - - - b - - - - - - - -
17
12 
yrs M a a - - - - + - - - - - - -
18
10 
yrs F a a - - - - + - - - - - - -
19
10 
yrs M a b + + a - + + a - - - - -
20 4 yrs F b b + + a c + + b - + - - -
21 7 yrs M c a - - - - + - - - - - - -
22
10 
yrs F a b + + a - + + b + + - + -
23 5 yrs M c b - - - - + - - - - - - -
24 9 yrs F a b + + a - - + b - - - - -
25 9 yrs M a a - - - - + - - - - - - -
26 8 yrs F a b + + b a + + b - + - + -
27 5 yrs F a b + + a - - + b + - - + -
28
12 
yrs M a b + + a - + + b + - - - -
29
11 
yrs M b b + + a - - + b - - - - -
30
10 
yrs F d b - + a c - + a - - + - -
31
10 
yrs M a a - - - - + - - - - - - -
32
11 
yrs M d b + + a c + + b - - - - +
33 8 yrs M a b + + - - + - b - - - - -
34 7 yrs M c b + + a c + + b - - - + -
35 5 yrs M d b - - - - + - - - - - - -
36
11 
yrs M a b + + a a + + b - - - - -
37
11 
yrs M a b + + a - + + b - - - - -
38 2 yrs M a a - - - - - - - - - - - -
39 2 yrs M a b + + a a + + b - - - - -
40 7 yrs F a b + + a - + - b - + - - -
41 6 yrs M d b + + a - + + b - + - - -
42 7 yrs F a b - - - - + - - - - - - -
43 1 yr M a a + + - - + - b - + - - -
44 7 yrs F a b + + a c + + b + + - - -
45 9 yrs M a a - - - - + - - - - - - -
46 8 yrs F b a + + b c + - a - - - - -
47
11 
yrs M b b - + b c + - b - - - - -
48 6 yrs F a b + + a - + + b + + - - -
49
11 
yrs M a b + + - - - + b - - - - -
50 5 yrs F a b + + a - + + b - + - - -
51
10 
yrs F b b - + a c + - - - - - - -
52 2 yrs M a b + + a - + - b - - - - -
53
10 
yrs M a a - - - - + - - - - - - -
54
12 
yrs M a b - - - a + - - - - - - -
55 4 yrs M d b + + a a + + a - + - - -
56 9 yrs M c b - + a c - - - - - - - -
57 5 yrs F a b - - - - + - - - - - - -
58 8 yrs M a a - - - - - - - - - - - -
59 6 yrs F a b - - - - + - - - - - - -
60 7 yrs M c b - - - - - - - - - - - -
61
11 
yrs M d a - - - a - - - - - - - -
62 8 yrs F d b + + a b & c + - a - - - + -
63 9 yrs F a b - - - - + - - - - - - -
64 1 yrs F d b - - - - - - - - - - - -
65
11 
yrs M a b + + a - + + a - - - - -
66 8 yrs M a b + + a - + + a - + - - -
67 9 yrs F a b - + a - + + a - - - - -
68 3 yrs M b b + + a - - + a - - - - -
69
11 
yrs M a b + + a - - + a + - - - -
70
12 
yrs M b b + + -  + + a - + - - -
71 9 yrs F a b + + a - - + a - - - - -
72
11 
yrs M a a - - - - + - - - - - - -
73 5 yrs F a b + + a b - + a + + - - -
74 6 yrs F a a - - - - + - - - - - - -
75 6 yrs M a a + + b a + - a a - + + -
76 8 yrs M a b + + - - - - a a - - - -
77
12 
yrs M d b + + a c - + a - - - - -
78 8 yrs M d a + + a c - - - - - + - +
79 9 yrs M a b - - - - - - - - - - - -
80 8 yrs M b b + + - c - - a - + - - -
81 8 yrs M b b + + a c + - a - - - - -
82 8 yrs F b b + + a c - - a - - - - -
83 7 yrs M a b - - - - + - - - - - - -
84 4 yrs M c b + + a c + + - - - - - -
85 4 yrs M a b - - - a - - - - -  - -
86 8 yrs F a b + + b - + - a - - - - -
87
11 
yrs M a b + + a a - + a + - - - -
88 5 yrs M a b - - - - + - - - - - - -
89
10 
yrs F d b - + a b - - a - - - - -
90
10 
yrs M a b - + a - - - a - + - - -
91
11 
yrs M a a + + - - - - a - - - - -
92
11 
yrs M a b - + a - + + a - - - - -
93
11 
yrs M d b + + a - - + a - + + - -
94
12 
yrs M b a + + a c + - a + + - - -
95 7 yrs M b b - + a c - - a + + - - -
96 9 yrs M a b + + a - + - b - + + - +
97 5 yrs M a b + + b c - + a - - - - -
98 9 yrs M a b + + a a + + a - - - - -
99  yrs M d a + + a a - - a - - + - -
100
10 
yrs M a a + + a - _ + a - + - - -
101 1 yr M a b + + a - + + a a - - - -
102
12 
yrs F a b + + - a - - a - + - - -
103 9 yrs F a b - - - - + - - - - - - -
104 8 yrs F a b - + a a + + a - - - - -
105
10 
yrs M a b + + a - - - a - + - - -
106 7 yrs F c b - - - - - - - - - - - -
107 3 yrs M a c + + - - - - a - - - - -
108
12 
yrs F a b + + a - + + a - - - - -
109 6 yrs M a a - + a - - - - - - - - -
110 6 yrs M a a - - - - + - - - - - - -
111 3 yrs M a b - - - - + - - - - - - -
112 6 yrs M a b + + - - + - a - - - - -
113
12 
yrs M b b + + a a + + a - - - - -
114
12 
yrs M a b + + a - + + a - - - - -
115 5 yrs M c a + + - - + - a - - - - -
116
12 
yrs M b b - - - - - - - - - - - -
117
12 
yrs F a b + + a - + - b - + - - -
118
10 
yrs M b b + + - c + - a - - - - -
119
11 
yrs M d b + + - c - - a - + - - -
120 5 yrs F b b - - - b + - - - - - - -
121 6 yrs F a a - + a - - - a - - - - -
122 5 yrs F a b + + a - - + a - - - - -
123 4 yrs M d b - + b - - - a - - - - -
124
12 
yrs M d a - - - - + - - - - - - -
125 2 yrs M a a - + a - + - a + - - - -
126
11 
yrs F d b + + - a + - a - - - - -
127 2 yrs M d a + + - a + - a - - - - -
128 5 yrs F a b + + b - + - b - - - - -
129 9 yrs F a b + + a - + + a + - - - -
130
10 
yrs M b b + + a - + + a + - - - -
131 9 yrs M c a + + a - + - a + - + - -
132 9 yrs M d b + + a - - - a + + - - -
133
11 
yrs M d b - - - - + - - - - - - -
134 8 yrs M a b + + - a + - a - - - - -
135
11 
yrs M a b - - - - + - - - - - - -
136
11 
yrs M b b - - - - + - - - - - - -
137
12 
yrs M b b + + a c + + a + - - - -
138
11 
yrs F a b + + - - + + a - - - - -
139 7 yrs M a b + + a a + + a - - - - -
140
10 
yrs M a a + + a - + + a + - + - -
141 9 yrs M a a + + a - - + b + - + - -
142 3 yrs F b b + + - - + + a + - - - -
143
10 
yrs F a b + + a - + + b - - - - -
144 9 yrs F a b + + a - - + a + - + - -
145 8 yrs M b a + + a a - + a - - - - -
MASTER CHART
Duration of arrival:
a – <4 hrs, b – 4-8 hrs, c – 8-12 hrs, d – >12 hrs
Site of bite:
a – Upper limb, b – Lower limb
Type of bite:
a – Hemotoxic
b – Neurotoxic
Treatment history:
a – Injections
b – Incision and drainage
c – Antisnake venom
d – Incision and drainage and Antisnake venom
Number of vials of Antisnake venom:
a - <10 vials
b - >10 vials
Duration of hospital stay:
a - <5 days
b - >5 days
Outcome:
a – Alive
b – Dead 
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ALIVE DEATH
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ALIVE DEATH
Number of ASV given initially & Outcome
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ALIVE DEATH
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8
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COMPLICATIONS
ALIVE DEATH
A case of hemotoxic snake bite with cellulitis and blebs
A case with bite in the upper limb during sleep with cellulitis
A case of neurotoxic snake bite with respiratory failure
Cobra with hood
A case of snake bite with gangrene and loss of middle finger
A case of hemotoxic snake with renal failure receiving peritoneal dialysis
A case of snake bite with osteomyelitis of lower limb
A case of snake bite with Disseminated intravascular coagulation
Saw scaled viper brought to our casualty measuring 37 and 32 inches
